AKTX CEO Abizer Gaslightwala Buys Over 21,000 Shares
Abizer Gaslightwala, CEO of AKTX, purchased 21,063 shares on June 24, 2026.
Key Points
- AKTX CEO Abizer Gaslightwala purchased 21,063 shares on June 24, 2026, with the stock trading at $10.76.
- Shares of AKTX traded near $10.76 on Friday; several funds have reduced their positions.
- Analysts maintain a positive outlook with HC Wainwright & Co. setting a $27 price target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Abizer Gaslightwala, CEO of AKTX, made a significant move by purchasing 21,063 shares of the company on June 24, 2026. This insider activity did not involve a pre-arranged trading plan and reflects his direct interest in the company's stock.
Insider Buying and Selling at Akari Therapeutics, Plc
On June 24, 2026, AKTX saw notable insider activity. CEO Abizer Gaslightwala acquired 21,063 shares, while Interim CFO Kameel Farag bought 18,830 shares at an average price of $5.58. Both transactions were direct purchases, not part of any pre-planned trading program.
Other Institutional Activity in AKTX
Several institutional investors have adjusted their positions in AKTX. Armistice Capital, LLC drastically reduced its holdings by about 2,722,993 shares, leaving it with 973 shares valued at approximately $200,448. Similarly, Cresset Asset Management, LLC cut its stake by 821,954 shares, holding 514 shares worth around $105,889. IFP Advisors, Inc opened a new position with 186 shares valued at $1,809. CWA Asset Management Group, LLC and SmartHarvest Portfolios, LLC both exited their positions completely, while NewEdge Advisors, LLC also sold out.
Akari Therapeutics, Plc Stock Up 0.5%
Shares of AKTX traded near $10.76 on Friday. Despite the recent insider buying and institutional selling, the stock remains an area of interest. Analysts continue to monitor its performance closely.
$AKTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts have shown confidence in AKTX's prospects. On April 2, 2026, HC Wainwright & Co. maintained a 'buy' rating with a price target of $27. Earlier, Ladenburg Thalmann initiated coverage with a 'buy' rating and a target of $1 on January 5, 2026. These ratings suggest varying levels of optimism about the stock's potential.
About AKTX
AKTX operates in the biotechnology sector, focusing on developing treatments for rare diseases. The company is headquartered in the United States and continues to innovate in its field.
Bottom Line
Abizer Gaslightwala's purchase of over 21,000 shares highlights his belief in AKTX's future. While some institutional investors have decreased their stakes, analysts remain optimistic, with some setting high price targets. Investors should note that insider activities are often backward-looking indicators and may not reflect current market conditions.
Get Akari Therapeutics, Plc alerts
New 13F filings, insider trades, and analyst moves on $AKTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.